$INCY
Incyte Corporation
Biopharmaceutical company focused on oncology and inflammation with Jakafi as lead drug.
INCY key facts as of November 14, 2026
- Latest AI research report
- INCY Stock Analysis: Growth Beyond Jakafi (as of November 14, 2026)
- StockAlpha report sentiment
- Neutral (as of November 14, 2026)
- Analyst consensus
- Buy (2 Strong Buy, 11 Buy, 14 Hold, 1 Sell, 1 Strong Sell) (as of November 1, 2026)
- Analyst price target
- $136.47 mean (range $104.00 to $157.00) (as of November 20, 2026)
- Sector
- Healthcare
Analysis from Nov 14, 2026
INCY Stock Analysis: Growth Beyond Jakafi
Incyte closed at $120.97 on Friday, November 13, with analyst targets pointing above that level and recent data showing revenue growth. Its longer-term outlook depends on pipeline launches and managing the transition beyond Jakafi, while earnings volatility and valuation measures complicate the picture.
Previous Reports
INCY FAQ
What is StockAlpha's latest view on INCY?
StockAlpha's latest AI research report on Incyte Corporation (INCY), "INCY Stock Analysis: Growth Beyond Jakafi", was published on November 14, 2026 and rates the overall sentiment as neutral. Incyte closed at $120.97 on Friday, November 13, with analyst targets pointing above that level and recent data showing revenue growth. Its longer-term outlook depends on pipeline launches and managing the transition beyond Jakafi, while earnings volatility and valuation measures complicate the picture.
When was the INCY research last updated?
The most recent INCY report was published on November 14, 2026.
What do analysts expect for INCY?
As of November 1, 2026, the analyst consensus on INCY is Buy (2 Strong Buy, 11 Buy, 14 Hold, 1 Sell, 1 Strong Sell). As of November 20, 2026, the analyst price target is $136.47 mean (range $104.00 to $157.00).
Is this INCY research investment advice?
No. StockAlpha.ai research is AI-generated analysis for informational purposes only and is not investment advice. Analyst figures are third-party data. Do your own research before making investment decisions.
Keep exploring
- draft Incyte into a free practice contest: How to put the stock you just researched into a contest lineup at no real-money risk
- the healthcare sector brief for context on Incyte's peers: Today's sector-level news and moves around the stock